Bristol-Myers Squibb agreed to acquire Celgene Corp. in a record-sized $74 billion deal that will unite two drugmakers battling for advantage in a crowded market for innovative cancer treatments.
Both companies have faced investor wariness about their prospects in recent months. Bristol makes an immunotherapy drug called Opdivo that accounts for roughly a quarter of its sales but that has trailed a rival medication from Merck & Co. Celgene, meanwhile, has been looking for a follow-up for its blockbuster blood-cancer therapy Revlimid.
ncG1vNJzZmivp6x7o7jOqKSbnaKce6S7zGilnq%2BjZK6zwMico56rX2d9coWMaWhmaGNkr7O10q2mpWWdrrKzv4ysqK6hkpd6tbuMm6yyZZOauaixzZ5koqZdbIFursilo6KnnmK9qa3RpphmnJWWuQ%3D%3D